Literature DB >> 7514688

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.

M Aihara1, R M Lebovitz, T M Wheeler, B M Kinner, M Ohori, P T Scardino.   

Abstract

Prostate cancer is histologically heterogeneous as reflected in the 5 patterns of the Gleason grading system. Gleason grade correlates with volume, extent and prognosis. Serum prostate specific antigen (PSA) levels also correlate with tumor volume but the degree to which grade correlates with PSA has not been precisely defined. To quantify this relationship further, we prepared maps of each grade of cancer in 86 radical prostatectomy specimens from patients with clinical stage T2 cancer. The median per cent of the volume of cancer per prostate composed of grade 1 was 0%, while it was 1% for grade 2, 84% for grade 3, 5% for grade 4 and 0% for grade 5. We stained 95 cancer foci (grades 1 to 5) in 40 of these specimens for PSA. The presence and intensity (0 to 3+) of staining in more than 33,000 acini (or cells) correlated inversely with grade (p < 0.0001). Nearly all acini in grade 1 and most in grade 2 stained positive (2 to 3+) for PSA; 87% were positive but with less intensity in grade 3. While many grade 4 (79%) and grade 5 (49%) cells were positive, the intensity of staining was weak. Serum PSA levels correlated with total tumor volume (r = 0.67) but serum PSA levels per cm.3 of cancer decreased with increasing grade (r = -0.24 and p < 0.02). These studies confirm the strong inverse correlation between Gleason grade and the PSA content of prostate cancer. Since more than 85% of grade 3 acini stained for PSA and grade 3 made up the largest portion (84%) of cancer, the predominant contributor to serum PSA levels from prostate cancer was Gleason grade 3. The other grades contribute relatively little to the serum PSA levels either because of the small volume (grades 1 and 2) or the diminished PSA content (grades 4 and 5).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514688     DOI: 10.1016/s0022-5347(17)35302-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.

Authors:  John F Donohue; Fernando J Bianco; Kentaro Kuroiwa; Andrew J Vickers; Thomas M Wheeler; Peter T Scardino; Victor A Reuter; James A Eastham
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

2.  Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.

Authors:  Chiachien Jake Wang; James Ying; Payal Kapur; Bryan Wohlfeld; Claus Roehrborn; Dong W Nathan Kim
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

3.  Decreased expression of ferroportin in prostate cancer.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

4.  Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.

Authors:  J Hübler; F Sükösd; M Czipri
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

5.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

6.  Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA.

Authors:  Satoru Maruyama; Naoto Miyajima; Miyuki Bohgaki; Tadasuke Tsukiyama; Masahiko Shigemura; Katsuya Nonomura; Shigetsugu Hatakeyama
Journal:  Mol Cell Biochem       Date:  2007-08-25       Impact factor: 3.396

7.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Authors:  Eric G Bluemn; Ilsa M Coleman; Jared M Lucas; Roger T Coleman; Susana Hernandez-Lopez; Robin Tharakan; Daniella Bianchi-Frias; Ruth F Dumpit; Arja Kaipainen; Alexandra N Corella; Yu Chi Yang; Michael D Nyquist; Elahe Mostaghel; Andrew C Hsieh; Xiaotun Zhang; Eva Corey; Lisha G Brown; Holly M Nguyen; Kenneth Pienta; Michael Ittmann; Michael Schweizer; Lawrence D True; David Wise; Paul S Rennie; Robert L Vessella; Colm Morrissey; Peter S Nelson
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

8.  Prostate cancer - a biomarker perspective.

Authors:  Yanqiu Liu; Priti Hegde; Fengmin Zhang; Garret Hampton; Shidong Jia
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-29       Impact factor: 5.555

9.  Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.

Authors:  Malini Srinivasan; Anil V Parwani
Journal:  Diagn Pathol       Date:  2011-07-21       Impact factor: 2.644

10.  Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.

Authors:  Yu Liu; Ingrid J Hall; Christopher Filson; David H Howard
Journal:  Urol Oncol       Date:  2020-12-09       Impact factor: 2.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.